The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Afton Chemical Selects Idea Lab

18 May 2010 07:00

RNS Number : 0846M
Sopheon PLC
18 May 2010
 



18 May 2010

 

Afton Chemical Sparks "Passion for Solutions"

with Sopheon's Idea LabTM Software

 

Deployment Augments Company's Earlier Adoption of Sopheon Software for

 Innovation Process Automation, Portfolio Management and Resource Planning

 

MINNEAPOLIS and LONDON - May 18, 2010 - Sopheon, the international provider of software and services for product lifecycle management, announced today that Afton Chemical, a global leader in the manufacture of lubricant and fuel additives, has selected Sopheon's Accolade® Idea Lab idea development solution to enhance the company's product innovation processes. Already a user of Sopheon's software for innovation process automation, portfolio management and resource planning, Afton Chemical will deploy Idea Lab to generate, nurture and develop new product ideas. Initial implementation will provide access to the solution for all Afton Chemical employees in the company's EMEAI (Europe, Middle East, Africa and India) region.

 

Innovation is an important area of strategic focus for many of today's chemical manufacturers. In a recent PricewaterhouseCoopers survey, 65 percent of the participating chemical company CEO's said they plan to increase their investments in research and development over the next three years. That was more than any other sector except entertainment and media. A separate study determined that the top innovators will gain an edge over their peers from two factors: successful management of their product portfolios and strong idea management.

 

For Afton Chemical, the quest to improve ideation sprang directly from its growth strategies. "Our business goals are ambitious and challenging," said Alan Cotter, senior product manager for Afton Chemical's EMEAI region. "They are built around providing customer-based solutions within our existing markets. We have an excellent record of new product development, but saw a need to develop an enhanced approach to generating and capturing new ideas across the organization."

 

As a start to crafting that approach, a cross-functional team was formed to define the organization's ideation requirements. Emphasis was placed on key process features, with ease-of-use and administrative simplicity ranking high on the list. When it came to support for workflows of ideas, a telephone-based system was considered, as were several software solutions. According to Cotter, Sopheon's Idea Lab was chosen "because of its robust functionality, user friendliness and minimal administrative support requirements."

 

Idea Lab provides Afton with a comprehensive set of consistent, sustainable methods for successful ideation. It can be used to launch and manage campaigns, publicize and motivate participation, and establish communities of innovators within which ideas can be solicited and shared. The software supports scoring and filtering of ideas and provides a commons where users can converge, exchange thoughts and enhance concepts. Afton Chemical expects that, in addition to helping generate more high-value ideas, Sopheon's Idea Lab will encourage greater employee involvement and collaboration in innovation activities.

 

"Our company has a history of innovation," said Mike Lewis, vice president for Afton Chemical's EMEAI region. "Sopheon's idea development solution is intended to support us in our drive to establish 'Passion for Solutions' at the heart of our business."

 

Accolade® and Idea LabTM are trademarks of Sopheon plc.

All other trademarks and registered trademarks are the sole property of their respective owners.

 

For further information contact:

 

Barry Mence, Chairman

Sopheon plc

Tel : + 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

Tel : + 44 (0) 1483 685 735

Justine James / Kirsty Corcoran

Hansard Communications

Tel : + 44 (0) 20 7245 1100

Floor van Maaren

Citigate First Financial

Tel : + 31 (0) 205 754 010

Catherine Leftley /

Jonathan Wright

Seymour Pierce Corporate Finance

Tel: +44 (0) 20 7107 8000

 

 

About Afton Chemical

Afton Chemical Corporation is a wholly-owned subsidiary of NewMarket Corporation (NYSE:NEU). Afton Chemical develops and manufactures petroleum additives that boost the performance of fuels and lubricating oils to achieve increased efficiency, power and durability in machinery, vehicles, and other equipment. From custom-formulated chemical blends to market-general additive components, Afton Chemical technology helps fuels burn cleaner and more efficiently, engines run smoother, and machines last longer. For more information, please visit www.aftonchemical.com.

 

About Sopheon

Sopheon (LSE:SPE) is an international provider of software and services that help organizations improve the business impact of product innovation. Sopheon's solutions automate and govern the innovation process, enabling companies to increase revenue and profits from new products. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKKODDCBKDNPD
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.